Why the study?
There were no specific viral protein-targeted therapeutics for COVID-19, and the structural information of the SARS-CoV-2 nucleocapsid protein was not yet clear.
Population
SARS-CoV-2 nucleocapsid protein N-terminal RNA binding domain
Comparison
Comparison with other reported coronavirus nucleocapsid protein N-terminal domains, including HCoV-OC43
Design
In vitro crystal structure analysis and binding study
Authors
Loading...
May inform selective nucleocapsid inhibitor design; leaves open clinical translation pending functional validation.
The determination of the SARS-CoV-2 nucleocapsid protein RNA binding domain structure provides atomic resolution features that could guide the design of novel targeted antiviral agents.
Kang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: